Karina Dias Teixeira

Dr. Karina Dias Teixeira


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
JVJosé Vitorino
José Vitorino
JMJorge Mansur Medina
Jorge Mansur Medina
KTKarina Dias Teixeira
Karina Dias Teixeira
MCMichael Chorev
Michael Chorev
ADAurora Diotallevi
Aurora Diotallevi
ULUlisses G. Lopes
Ulisses G. Lopes
Protein synthesis has been a very rich target for developing classes of drugs to control prokaryotic and eukaryotic pathogens. Despite the development of new drug formulations, treating human cutaneous and visceral Leishmaniasis still needs significant improvement due to considerable side effects and low adherence to the usual treatment regimen. In this work, we show that the di-substituted urea-derived compound I-17 is effective in inhibiting the promastigote forms and intracellular amastigotes of the Leishmania (L.) amazonensis and L. infantum species, in addition to exhibiting low macrophage cytotoxicity. We also show a potential immunomodulatory effect of I-17 in infected macrophages, which exhibited increased expression of inducible Nitric Oxide Synthase (NOS2) and Nitric Oxide (NO) production. Our data suggest that I-17 and new derivatives of this compound may be helpful in developing new drugs for treating leishmaniasis.